Engineering Genes, Vectors, Constructs and Clones
Sriram Kosuri, Ph.D.,
Assistant Professor, Chemistry and Biochemistry, University of California, Los
Dr. Kosuri received his B.S. in
Bioengineering from the University of California at Berkeley in 2001, where he
conducted research on bacterial systems biology with Dr. Adam Arkin. In 2007,
he received his Sc.D. in Biological Engineering at MIT working with Dr. Drew
Endy. His research focused on developing simulations and models of
bacteriophage T7 gene expression, and testing these models by redesign and
synthesis of the T7 genome. During this time he co-founded OpenWetWare, and
helped the initial development of the MIT Synthetic Biology Working Group and
iGEM. After graduate school, he helped start Joule Unlimited, which is focused
on developing fuels from light and CO2 using engineered cyanobacteria. In 2009,
he joined Dr. George Church’s lab and the newly created Wyss Institute
conducting research on next-generation technologies in DNA synthesis and
multiplexed assays of gene expression. He will be joining the Chemistry and
Biochemistry Department at UCLA in January 2014.
Ph.D., Technical Director, Recombinant Antibody Network, Biochemistry and
Molecular Biology, The University of Chicago
Dr. Paduch is a Technical Director of Synthetic Antibody &
Crystallography Core Facility at The University of Chicago and manages an
antibody generation pipeline serving the NIGMS PSI:Biology program, Membrane
Protein Structural Dynamics Consortium, Chicago Biochemical Consortium and NIH
Common Fund Protein Capture Reagents Program under the umbrella of the
Recombinant Antibody Network (RAN). His work is focusing on expression,
purification and biophysical characterization of proteins followed by antibody
engineering and validation. Since joining the RAN consortium he has been
instrumental in developing high-throughput phage display methodologies and
automation systems supporting recombinant antibody generation projects.
Yongping Crawford, Ph.D.,
Scientist, Early Stage Cell Culture, Genentech, Inc.
Crawford is a Scientist in the Department of Early Stage Cell Culture at
Genentech. Her primary responsibilities are to lead research associates in
developing Phase I/II and III cell lines for supporting the pipeline; to
develop/apply new technologies for cell line development (CLD); and to engineer
host cells aimed at improving and simplifying the CLD process. She was trained
as a cancer biologist. Crawford received her Ph.D. from UCSF and continued her
training as a postdoctoral fellow at Genentech Research organization.
Wei Chen, Ph.D., Managing
Director, BioPharmaneer, Inc.
Dr. Wei Chen
has over 25 years of biopharmaceutical industry experience in managing multiple
biologic product development and cGMP manufacturing operations for both clinical
and commercialization. Based on an integrated technology approach combining
biology, process, engineering and regulatory principles, he has led and
design-built a number of the most cost-effective cGMP biologic manufacturing
facilities and operations with successful regulatory inspections for
multi-products. His responsibilities and expertise include technical team
building/training, vector-cell lines development, process/analytical
development/scale up, quality assurance, quality control, validation, facility
engineering and CMC regulatory submissions. Types of products include
monoclonal antibodies, scFv, Fab, ADC, recombinant protein therapeutics,
vaccines, viral and DNA vectors, gene/cell therapies, cytokines, hormones,
immunomodulators, enzymes, antibiotics, cancer therapeutics, etc. Dr. Chen has
held positions at Bristol-Myers Squibb, Centocor/J&J, Immunomedics,
BioReliance, Corautus/Baxter, Symbigene and Phage. Dr. Chen has a Ph.D. in
Bioreaction Engineering and did postdoc research at Yale University, University
of British Columbia and UCLA.
Roland Weis, Ph.D., Head, Operations, VTU Technology GmbH
Roland Weis, Head of Operations, completed his M.Sc. in microbiology at Karl-Franzens-University Graz and holds a Ph.D. in molecular biotechnology from Graz University of Technology. After his engagement in a bilateral project with Pasadena-based BioCatalytics, Inc., he was appointed authorized representative and scientific director of BioCatalytics Europe GmbH in Grambach, Austria. In 2007, he joined VTU Technology to head the operational team for high throughput protein production with Pichia pastoris.
James L. Hartley, Ph.D., Senior Scientist,
Protein Expression Laboratory, Advanced Technology Program, Frederick National
Laboratory for Cancer Research
worked at Life Technologies, Inc. / Invitrogen, where he helped develop the
Gateway cloning technology. Since 2001
he has been in the Protein Expression Laboratory of the Advanced Technology
Program at the Frederick National Laboratory for Cancer Research.
Jr., Ph.D., Assistant Professor, Chemistry and Biochemistry, Ohio University
and CSO, Molecular Technologies Laboratories, LLC
Kittle, Jr. is Assistant Professor of Chemistry and Biochemistry at Ohio
University and CSO of Molecular Technology Labs, an established contract
research organization that has top-tier pharma and biotech clients. Dr. Kittle
was formerly SVP, Research and Technology at Coda Genomics (now Verdezyne) and
Senior Director, Research at Lark Technologies. He did his graduate work at
Harvard University with Nancy Kleckner and a postdoctoral fellowship with Alan
Lambowitz at The Ohio State University.
Curtis Knox, Vice President, Marketing & Sales, Lucigen Corp.
Curtis Knox is currently the Vice President of Marketing & Sales for Lucigen, where he has been since 2011. He has 20 years of experience as a scientist and product development specialist in the areas of molecular biology, forensics, and molecular diagnostics, focusing primarily on sequencing and genotyping applications. Mr. Knox holds a B.S. in Genetics from Iowa State University and an MBA from the University of Wisconsin-Whitewater.
Partha Chowdhury, Ph.D., Principal Scientist, Antibody Discovery and Protein Engineering, MedImmune, Inc.
Dr. Chowdhury is Principal Scientist in Medimmune, leading a group of 12 scientists in the area of antibody technology development and drug discovery. Dr. Chowdhury has 20 years of experience in the field of antibody drug discovery and development and is author and co-author of many peer-reviewed papers and patents.
Chaminda Salgado, Head, CMC
Bioassay and Genomics, CMC Bioassay and Genomics, NDA-Analytics
Chaminda developed his expertise in real-time QPCR in 1996, whilst
working for the U.K. Ministry of Defence at Porton Down, where he was involved
in rapid portable instruments/assays for the purpose of deployment to
battlefield environments, weapons inspectorates and homeland security for the
detection of Biological Weapons, using molecular biological techniques
including real-time PCR. He then moved to GlaxoSmithKline
(Biopharmaceutical CEDD) in 2000, where he was involved in CMC drug/cell
line/process development and characterisation, and driving the global strategy for
real-time PCR. He also took CMC Analytical Leadership roles for several
Biopharmaceutical projects, and CMC Project Lead roles for some DNA Vaccine
projects.In his current role he leads the CMC in vitro/ex vivo potency
and molecular biology teams. Chaminda is a Key Opinion Leader for the Roche
LightCycler family of instruments and has provided guidance to Lifetechnology
reagent/kit development. He is co-author of “Real-Time PCR: Advanced
Technologies and Applications”.
James E. Galen, Ph.D., Professor, Medicine, Chief, Salmonella Live
Vector Vaccine Section, University of Maryland School of Medicine
I have been involved for over 15 years with the construction of
attenuated bacterial vaccines, and their use as live vectors for delivery of
foreign antigens to the human immune system. Over the last decade, I have
focused on the development of plasmid-based expression systems for delivery of
foreign antigens from both prokaryotic and eukaryotic organisms, and have
genetically engineered a novel antigen transport system for export of antigens
out to the surface of attenuated S.Typhi. I have also engineered a novel
plasmid stabilization and selection system which removes the need for plasmid
selection using antibiotics and guarantees plasmid retention in vivo after introduction into live
vector strains. I have applied these advances in expression technology to the
development of biodefense vaccines targeting diseases caused by Bacillus anthracis and Yersinia pestis. I have recently begun
to develop chromosomal expression technologies for delivery of multiple foreign
antigens, which will be required in future efforts to develop multivalent live
vector vaccines with the capacity to elicit protective immunity against one or
more pathogens without the need for combining several strains into a single
Mark Welch, Ph.D., Director, Gene Design, DNA2.0, Inc.
Dr. Welch received his Ph.D. in 1996 for work in the laboratory of Dr. Michael Yarus at the University of Colorado at Boulder where he studied of the role of 23S ribosomal RNA in translation. From 1998 to 2002, Dr. Welch worked on development and application of directed protein evolution technologies at Maxygen. Subsequently, he held positions in protein engineering technology development at Kosan Biosciences and Applied Biosystems before joining DNA2.0 in 2007 as Director of Gene Design.
Lawrence J. Tartaglia, Ph.D., Research Scientist, Biochemistry and Molecular Biology, Center for Structural Biology, University of Florida
Lawrence Tartaglia received his undergraduate degree in biology from Rutgers University in 2003. In 2007, he obtained a master’s degree in molecular biology for research on the psychrophilic ice worm, Mesenchytraeus solifugus, under the supervision of Dr. Daniel H. Shain. In this study he used molecular and biochemical techniques to determine how ice worm microtubules remain functional at low physiological temperatures. In 2008, he joined Dr. Mavis Agbandje-McKenna’s lab at the University of Florida, Department of Biochemistry and Molecular Biology, for his Ph.D. thesis research project focused on the characterization of the interaction of Adeno-associated virus serotype 2 (a promising gene delivery vector) and its integrin co-receptors. His studies involved the development of constructs for the expression and purification of recombinant αVβ5 and α5β1 integrins in various expression systems. The interactions were characterized using multiple techniques including surface plasmon resonance and cryo-electron microscopy. He received his Ph.D. in the summer of 2013.
Domenico Maione, Ph.D.,
Unit Head, Cloning and Expression, Novartis Vaccines and Diagnostics
Dr. Maione is Head of the Cloning and
Expression Unit at Novartis Vaccines and Diagnostics Siena, Italy. He has
longstanding experience in the vaccinology field. He is contributing to the
development of vaccines against bacterial and viral pathogens, with particular
focus on Group B Streptococcus. His
main interests are antigen discovery and characterization, protein expression
and structural studies. Dr. Maione received a Ph.D. in Genetics and Molecular
Biology from University of Rome – La Sapienza.
Abdulrahman, Ph.D., Research Scientist, Mechanisms of Cancer, Friedrich
Miescher Institute for Biomedical Research and CPC Novartis
During more than seven years, I
developed methods to simplify and improve the quality of protein samples
production in insect cells. I specialized in designing construct-generation
tools for the expression of multi-protein complexes, a bottleneck which
academic and fundamental researchers must face to investigate new targets. The
tools I established became widely used in the platform of genomics and
structural biology at IGBMC institute in Strasbourg where I received my Ph.D.
in 2009. Thanks to this success I was recruited at Friedrich Miescher Institute
(part of Novartis Institutes for Biomedical Research in Basel) to further
develop these techniques and adapt them to high-throughput screening.
Christoph Freiberg, Ph.D.,
Senior Scientist, Biologics Research, Bayer HealthCare
Freiberg, Ph.D., is a biologist working since 2007 as senior scientist and
project manager in Bayer HealthCare’s Biologics Research in Wuppertal, Germany.
He is heading a laboratory responsible for protein expression and cell line
development and is leading biologics data management as well as lead
optimization projects. Before, Christoph worked as Professor for Applied
Biochemistry and Bioinformatics in the Department of Chemistry at the
Niederrhein University of Applied Sciences in Krefeld, Germany, and as research
scientist and project manager in Bayer’s Antiinfectives Research and non-clinical
development. Christoph was educated at the Universities of Göttingen, Marburg
and Jena, Germany (diploma in Biology, Ph.D. in Molecular Biology).
Recombinant Protein Expression and Production
Lorenz M. Mayr, Ph.D., Vice President, Reagents & Assay
Development, AstraZeneca, Inc.
Lorenz has been working since September 2012 as
Vice President, Reagents & Assay Development with global responsibility for
generation of biological reagents and assay development activities at
AstraZeneca. This includes generation of proteins and cell lines for hit
finding, hit-to-lead and lead optimisation activities including structure and
biophysics activities across all therapeutic areas, the generation of tool
antibodies, transgenic animals, stem cells and primary cells as tools for
target validation studies and lead optimisation programmes. His department in
the U.K. and Sweden is responsible for assay development activities for
biochemical, cell-based and phenotypic assays for all therapeutic areas at
AstraZeneca. Before that, he has worked as Executive Director at Novartis
Pharma in Basel, Switzerland, at Bayer Pharma Research in Wuppertal, Germany,
at Bayer Central Research in Leverkusen, Germany and at the MIT/Whitehead
Institute in Cambridge, Massachusetts (U.S.A.). He has published more than 50
papers in peer-reviewed journals and serves on several editorial and scientific
advisory boards, including two terms on the Board of Directors for the Society
of Biomolecular Sciences (2004-2011), and has worked as the Conference Chair of
the MipTec Drug Discovery Conference, Europe’s largest drug discovery event,
held in Basel, Switzerland.
Ki Jun Jeong, Ph.D.,
Assistant Professor, Chemical and Biomolecular Engineering, KAIST
Prof. Ki Jun Jeong is currently
Assistant Professor in the Department of Chemical and Biomolecular Engineering,
KAIST. He obtained his Ph.D. in Chemical Engineering from KAIST in 2001 and he
joined Dr. George Georgiou’s research group in University of Texas at Austin
(USA) as a postdoctoral fellow. In 2008, he joined KAIST and currently, his
research is focused on protein/antibody engineering, including (i) antibody
engineering against various infectious diseases, (ii) development of new
scaffold proteins as alternative antibodies and (iii) systems/synthetic biology
for efficient production of antibody and antibody fragments in bacterial
system, and mass production by high-cell-density cultivations.
Glenn F. King, Ph.D.,
Research Scientist, Institute for Molecular Bioscience, University of
Glenn did his Ph.D. at the University of Sydney
(USYD) before postdoctoral studies at the University of Oxford. After academic
stints at USYD and the University of Connecticut Health Center, he joined the
Institute for Molecular Bioscience at the University of Queensland in 2007,
where he is currently a NHMRC Principal Research Fellow. The focus of Glenn’s research
is venoms-based drug discovery, in particular the development of eco-friendly
insecticides and analgesics. Glenn’s research on
insecticidal spider-venom peptides led to his founding of Vestaron Corporation,
an agricultural biotechnology company focused on development of eco-friendly
insecticides. In recent years, his attention has turned to the development of novel anti-pain
therapeutics (analgesics) based on venom peptides that modulate the activity of
either ligand- or voltage-gated ion channels in primary sensory neurons.
Several molecules discovered in his lab have already progressed to preclinical
studies. Glenn has published 175 journal articles and
book chapters and he currently serves on the Scientific Advisory Board of three
companies and the Editorial Board of four journals. He is a former President of
the Australian Society for Biophysics and a Fellow of the American Academy of
James M. Rini, Ph.D.,
Professor, Molecular Genetics and Biochemistry, University of Toronto
James Rini obtained his
Ph.D. at the University of Toronto where he studied protein-carbohydrate
interactions using x-ray crystallography, NMR and other biophysical techniques.
His postdoctoral work at the Scripps Research Institute in La Jolla, CA, was
aimed at understanding the structural and mechanistic basis for the specificity
shown by anti-peptide antibodies. He is now a full professor at the University
of Toronto where his research interests are focussed on: i)
glycosyltransferases and ER quality control, ii) coronavirus-receptor
interactions and iii) the role of IgG Fc glycosylation. In all cases, the work
is cross-disciplinary in nature involving structural, biochemical and
Igor Fisch, Ph.D., CEO, Selexis SA Dr. Igor Fisch co-founded Selexis SA in March 2001 and has been the company’s Chairman and CEO since its inception. Igor brings the company his extensive network amongst key decision makers in the Biotech and Pharmaceutical industry and has a demonstrated track record for executing major licensing deals in the industry worldwide. Igor is a member of the Board of Directors of Affitech A/S. He co-founded BioXpress SA and sits on its advisory board and is on the board of the Venture kick initiative. An accomplished protein chemist and molecular biologist, Igor previously was a professor at the Center for Biotechnology at the University of Lausanne and the EPFL. He obtained his PhD under the direction of Professor Robin Offord at the University of Geneva and pursued his post-doctoral studies in the laboratory of Prof. Sir Gregory Winter at the Medical Research Council (MRC) in Cambridge, UK. In parallel to his research and teaching activities, Igor obtained several awards including the De Vigier Prize and the NETS Best Prize.
John Proctor, Ph.D., Director, Corporate Development, ProteinSimple
John Proctor is currently the Director of Corporate Development at ProteinSimple leading Marketing efforts for both the Simple Western and Imaging product families. John earned a Ph.D. in Neuroscience studying the role of integrins during vascular development of the brain and the University of California in San Francisco. Since then, he has been developing and marketing various novel and innovative technologies for cell-based drug screening, biomoleular interaction analysis, and protein analysis.
Karl E. Griswold, Ph.D.,
Associate Professor, Thayer School of Engineering, Dartmouth College
Karl Griswold is an Associate
Professor at the Thayer School of Engineering at Dartmouth. His work in the
field of combinatorial protein engineering has resulted in the development of
novel strategies for gene library construction and new approaches to
high-throughput screening of recombinant enzyme libraries. At the Thayer
School, his research group is seeking to develop and utilize tools for
evolutionary protein engineering while placing a priority on designing therapeutic
enzymes with practical utility in treating human disease. His work on
antibacterial biocatalysts has been recognized with the Coulter Foundation
Early Career Translational Research Award in Biomedical Engineering, as well as
numerous grants from the Cystic Fibrosis Foundation and the National Institute
for Allergy and Infectious Disease.
Per Amstrup Pedersen,
Ph.D., Professor, Biology, University of Copenhagen
Per Amstrup Pedersen is
Professor at the Department of Biology, University of Copenhagen, Denmark. His
research focuses on high-yield production and purification of recombinant
eukaryotic membrane proteins for biochemical and structural characterization.
He is highly engaged in discovering the potentials of membrane proteins in
industrial separation and sensing technologies through a 15 million dollar
enterprise. In vivo protein mal-folding is a
challenge faced in recombinant membrane protein production as well as in
patients suffering from certain genetic diseases. Identification of chemical
chaperones to circumvent this problem is another focus point of his research.
Alexei Yeliseev, Ph.D.,
Staff Scientist, Protein Biochemistry, LMBB, National Institutes of Health
Alexei Yeliseev received his
Ph.D. in biochemistry in 1987 from the Russian Academy of Sciences in Moscow
and did his postdoctoral research in enzymology of methanogenesis with Rolf
Thauer at Philipps-University in Marburg, Germany and on molecular biology and
biochemistry of vitamin B12 biosynthesis with Sir Alan Battersby at Cambridge,
UK. From 1993-1999 he worked as a Senior Research Fellow on regulation of
microbial photosynthesis at the University of Texas Medical School at Houston
before moving to a position of Senior Scientist at Hoffmann-La Roche and later,
Senior Scientist at Kosan Biosciences, Inc. He joined the NIH in 2003 and
currently heads the protein biochemistry group with responsibility for
developing technologies for expression, purification and analysis of
recombinant G protein-coupled receptors. In addition to his research work he
serves as a member of the editorial board of Protein Expression and Purification and Journal of Receptor, Ligand and Channel Research.
Michael D. Burkart, Ph.D.,
Professor, Chemistry and Biochemistry, University of California, San Diego
Mike Burkart received a B.A. in chemistry from Rice University in
1994 and Ph.D. from Scripps Research Institute in 1999. Following postdoctoral
studies at Harvard Medical School, he started his lab in 2002 at University of
California, San Diego, where he is currently a Professor of Chemistry and
Biochemistry and Associate Director of the California Center for Algae
Biotechnology. He is the recipient of the Ellison New Scholar Award, the NSF
CAREER Award, an American Cancer Society Research Scholarship, the Alfred P.
Sloan Fellowship and is an NIH Eureka recipient. His research interests include
natural product synthesis, biosynthesis and metabolic engineering.
Russell Coleman, Senior Scientist, Pfenex Inc.
Senior Scientist in Molecular Biology supporting projects within Pfenex’s Product Development and Strain Engineering-based businesses. Contributed to the development of the Pfenex Expression technology platform for over 11 years.
Zhimei Du, Ph.D., Senior
Scientist, Cell Sciences & Technology, Amgen, Inc.
Zhimei Du earned a Ph.D. from
Cornell University Medical College, Immunology Program, studying the regulation
of Jak/Stat signaling pathways during innate immune response. After graduation,
she joined Robert G. Roeder’s laboratory at Rockefeller University, studying
transcriptional regulation mechanism and epigenetic effects during early B cell
development. After three years, she was recruited by Regeneron’s antibody
engineering group, focusing on bi-specific Ab development. Later, she joined
Amgen’s Cell Sciences &Technology department, focusing on cell line
Mark Tié, Associate
Scientist, Cell Culture Development, Biogen Idec
Mark Tié received a BS from
the University of Vermont. He is in the process of completing coursework for
his Master’s degree.
Mario M. Alvarez, Ph.D., Professor, Engineering
and Architecture and Director, Centro de Biotecnología-FEMSA, Tecnológico de
Monterrey at Monterrey
Mario Moisés Alvarez received
a Ph.D. from Rutgers University and conducted a postdoctoral stay at the
Institute of Pharmaceutical Research at Bristol-Myers Squibb. He is currently a
full professor and director of the Biopharmaceutical Engineering Group at the
Centro de Biotecnología-FEMSA at Tecnológico de Monterrey in México. He has
published more than 55 papers in international journals including PNAS, Journal of Virology, Lab on a
Chip, PLOS One, Biotechnology and Bioengineering and Biotechnology Progress. His work has
been cited more than 800 times in scientific literature.
Inci Ozdemir, Ph.D., Senior
Scientist, Culture Process Development, Pfizer, Inc.
Inci Ozdemir received her
Bachelor of Science degree in Chemical Engineering with a minor in Biology in
2006 from the Middle East Technical University, Turkey. She wanted to be more
intellectually engaged in the biotechnology track of chemical engineering and
to live abroad. These two dreams took her to the United States. She enrolled in
a Ph.D. program in Chemical and Biomolecular Engineering with a minor in
Biotechnology at NC State University. Inci Ozdemir has conducted research using
extremely thermophilic species in the graduate school; she got experienced in
molecular biology, fermentation technology and downstream processing. After
finishing her doctorate degree in 2012, she joined Pfizer, St. Louis, MO.
Currently, she is working as a Senior Scientist at Bioprocess R&D
Biotherapeutics Pharmaceutical Sciences, Culture Process Development, Pfizer,
Kristin DeFife, Ph.D., Director, Biologics, Ajinomoto Althea
Dr. DeFife is the Director of Biologics at Ajinomoto Althea and has over fifteen years of successful leadership and biologics development and manufacturing experience in the biotechnology industry. Most recently, she served as VP of Operations at PacificGMP, a biologics contract manufacturing organization. Prior to her tenure at PacificGMP, she held the position of VP of Research and Development at MediVas, LLC as well as scientific positions at Immusol Inc. and CyThera and was engaged in the development of therapeutic recombinant biologics. Dr. DeFife received her Ph.D in Pathology from Case Western Reserve University and a B.S. in Biological Sciences, Magna Cum Laude, from Quincy College.
Vidadi Yusibov, Ph.D., Executive Director,
Fraunhofer USA Center for Molecular Biotechnology
Dr. Vidadi Yusibov is
Executive Director of Fraunhofer USA Center for Molecular Biotechnology, where
he is responsible for the oversight of all plant-based vaccine and therapeutic
development programs. For over 20 years, Dr. Yusibov has been involved in a
variety of aspects of plant molecular biology, with a major focus on using
plants as a means for biomanufacturing. Prior to joining Fraunhofer USA Center
for Molecular Biotechnology, Dr. Yusibov was an Assistant Professor at Thomas
Jefferson University, where he was part of a team that developed a plant
virus-based experimental vaccine against rabies, which was transitioned into
clinical trials. Previously, Dr. Yusibov held a research position at Purdue
Miller Tran, Ph.D., Senior Scientist, Triton
Miller Tran received his Ph.D. from the University of California,
San Diego and is a co-founder of Triton Algae Innovations. Dr. Tran has spent
his career focusing on the development of the algal chloroplast recombinant
protein expression platform. In numerous publications, Dr. Tran has
demonstrated the versatility of algal chloroplast in folding and assembling
complex mammalian proteins such as full-length human antibodies. Additionally,
he has demonstrated the unique ability of chloroplasts to assemble and
accumulate complex immunotoxin proteins. As a scientist in Triton, Dr. Tran
continues to pursue the development of immunotoxin therapy using algae as an
Transient Protein Production
Sabine Geisse, Ph.D., Director/NLS, Novartis Institutes for
Sabine Geisse’s major focus of expertise is in eukaryotic cell biology
with 25 years of experience. She holds Ph.D.s in Nutrition and Human
Biology awarded by the Justus-Liebig-University in Giessen and
Philipps-University in Marburg, respectively. Following a postdoc period at the
University of Essen, Germany, she joined Sandoz/Novartis in 1988 within the
Discovery Technologies department. In 2004, she received the Novartis Leading
Scientist award. As a group leader, her team is responsible for the recombinant
production of biomolecules such as antigens and antibodies.
Jong-Mook Kim, Ph. D.,
Head, Cell Science Team, R&D Division, Celltrion Inc.
I am a head of Cell Science Team
at R&D Division, Celltrion Inc. Currently, I am focused on development of
mammalian cell line expressing recombinant protein.
Athena Wong, Ph.D., Scientist,
Early Stage Cell Culture, Genentech, Inc.
Athena Wong is a Scientist in the Department
of Early Stage Cell Culture at Genentech where she has worked in the field of
transient transfections for over eight years. She leads a group which supports
material generation for discovery and preclinical studies through the use of
transient transfections and stable pools. Her group’s efforts in transfection
optimization include the evaluation of new HEK293 and CHO host cell lines as
well as the development of automated, small-scale transfection systems. Athena
holds a Ph.D. from the University of North Carolina at Chapel
Hill and B.S. from the University of California at Davis.
James Brady, Ph.D., Director, Technical Applications, MaxCyte, Inc.
Dr. Brady received a B.S. in Biology from the College of William and Mary and a Ph.D. in Genetics from Indiana University. Following a postdoctoral fellowship in the National Eye Institute of the National Institutes of Health, Dr. Brady worked for four years at MetaMorphix, Inc. as a Senior Scientist and as a Group Leader in the Company’s Transgenic Livestock program, where he managed internal and external projects focused on improving livestock by modifying the activity of growth and differentiation factors. Later, Dr, Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders. Since 2004, has been with MaxCyte, Inc., where he serves as Director of Technical Applications.
Hao Chen, Ph.D., Senior
Scientist, Protein Technologies, Amgen, Inc.
Dr. Hao Chen is a Sr. Scientist at the
Department of Protein Technologies, Amgen Inc. He is currently working on
cloning, protein expression and engineering using multiple platforms for drug
discovery. Before joining Amgen, he was a postdoctoral fellow in the laboratory
of Dr. Gerald Fink at Whitehead Institute/MIT after obtaining his Ph.D. in
Molecular Biology and Biochemistry from Rutgers University/HHMI, under the
supervision of Dr. Richard Ebright.
Lars Kober, Ph.D.,
Scientist, Cellca GmbH
Dr. Lars Kober is a bioengineer
focused on Cell Line Development and Media Development. He has performed his
doctoral thesis under the supervision of Prof. Jürgen Bode and received his
degree with honors from the Technical University Braunschweig. As Head of
Quality Management he was in charge of planning and implementation of a very
effective quality management system at Cellca GmbH.
Yvonne J. Rosenberg, Ph.D.,
CEO, PlantVax, Inc.
Dr. Rosenberg is Founder and CEO of PlantVax, Inc., a
biotechnology company in Rockville, MD. PlantVax is developing
recombinant therapeutic proteins in plant and mammalian expression systems. The
focus of the research is production of highly neutralizing HIV mAbs to use
as passive immunotherapeutics to prevent HIV transmission or infections and the
production of an organophosphate bioscavenger pretreatment to prevent
neurotoxicity resulting from nerve agent or pesticide exposure. Dr.
Rosenberg received her Ph.D. from the Australian National University, Canberra,
Australia in immunology and completed her postgraduate studies at the NIH and
Ph.D., Senior Scientist, Fraunhofer USA Center for Molecular Biotechnology
Musiychuk is a Senior Scientist at Fraunhofer USA Center for Molecular
Biotechnology (FhCMB), where he leads The Molecular Engineering group. He is
tasked with gene and protein design, gene optimization, cloning and vector
development. His lab is also focuses on developing strategies to improve and
optimize gene expression in plants. Results produced in his group were
published in peer-reviewed journals, included in IND applications to the FDA
and presented at multiple scientific meetings. Dr. Musiychuk obtained his Ph.D.
from Vavilov Institute of General Genetics, Moscow, Russia in Molecular Biology.
Ph.D., Research Scientist and Adjunct Professor, Biology, Agriculture and
Agri-Food Canada, Western University
Dr. Rima Menassa has over 15 years
of experience working on recombinant protein production in plants as a research
scientist at Agriculture and Agri-Food Canada. She has worked with
pharmaceutical proteins, mainly focused on the treatment of autoimmune
diseases, and industrial proteins, such as spidersilk proteins and cell wall
degrading enzymes. She has established several plant expression systems,
including transient Agro-infiltration in Nicotiana
benthamiana and tobacco, nuclear and chloroplast transformation in tobacco
and BY-2 cell suspensions. Dr. Menassa received her Ph.D. from McGill
University in Montreal.
Ph.D., Head, Biotechnology Core Laboratory, National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), NIH
Joseph Shiloach is the head of the Biotechnology Core laboratory at the NIDDK/NIH; he
has been involved in various biotechnological topics since 1980. The laboratory
specializes in the large-scale production and
purification of biological materials from various sources to advance research
in fields such as vaccines, structural biology and drug development. To achieve
this goal, the lab integrates two main functions: (1) production which is done
in a multipurpose, state-of-the-art pilot production facility and (2) research
and process development that is conducted by performing independent
biotechnology research towards solving biological production issues through the
utilizing of physiological, molecular biology and technical approaches.
Rüdiger Neef, Ph.D.,
Principal Scientist, USP Development, Amgen, Inc.
Currently I am Principal
Scientist at Amgen Research Munich and responsible for upstream development
(cell line generation and fermentation) and technology transfer. I had the same
function at Micromet and came to Amgen via the acquisition of Micromet by Amgen
in 2012. After obtaining my master of biology with the focus on genetics,
biochemistry and immunology from the University of Munich, Germany I was
research assistant at the Albert Einstein College of Medicine in NYC. Coming
back to Munich, I did my Ph.D. at the Institute for Immunology of the
University of Munich working on the molecular mechanism of metastasis of human
melanoma. Before joining Micromet/Amgen I did a long year postdoc at the
Max-Planck Institute of Biochemistry, Martinsried, Germany in the Department of
Cell Biology, studying cell cycle regulation by mitotic kinases and motor
Sharfstein, Ph.D., Associate Professor, Nanobioscience, Nanoscale Science and
Engineering, University at Albany, State University of New York
Sharfstein received her B.S. in chemical engineering with honors from Caltech
in 1987 and her Ph.D. in chemical engineering from UC Berkeley in 1993,
receiving graduate fellowships from the university and the National Science
Foundation. She received a National
Institutes of Health Individual Research Service Award to pursue postdoctoral
studies, initially at UC Berkeley and subsequently at the UCLA Medical School.
Dr. Sharfstein joined the faculty at the University of Toledo in Bioengineering
in 1996. In 2000, she received a National Science Foundation POWRE award to
study glycobiology at the New York State Department of Health Wadsworth
Laboratories. In 2001, she joined the Department of Chemical and Biological
Engineering at Rensselaer Polytechnic Institute and in 2007 she received a dual
appointment in Biology. In 2010, she joined the faculty at the College of
Nanoscale Science and Engineering at the University at Albany as an Associate
Professor of Nanobioscience. Professor Sharfstein received an NSF CAREER grant
in 2000 for her work on hyperosmotic stress responses of hybridoma cells and
the School of Engineering Education Excellence Award and the Class of 1951
Outstanding Teaching Award in 2007. She is the author of over 40 papers and
book chapters in the field of mammalian cell biotechnology.
Henry C. Chiou, Ph.D.,
Senior Product Manager, Life Technologies
Dr. Chiou has over 15 years
of experience working on development of mammalian protein expression systems
and transfection reagents. For the past nine years he has worked as a principal
scientist and now in product development and portfolio management for Life
Technologies. He has led the development efforts on a number of products,
including the FreeStyle™ transient expression systems, Lipofectamine™ LTX and
Lipofectamine™ RNAiMAX. Prior to Life Technologies, he worked for several
biotech companies on biotherapeutic gene delivery systems. Dr. Chiou received
his doctorate from Harvard University and completed a postdoctoral fellowship
at the University of Pennsylvania.
Jianming Liu, Ph.D., Senior
Scientist, Discovery Sciences, AstraZeneca, Inc.
Dr. Jianming Liu is currently a
Senior Scientist in the Reagents & Assay Development Department of
Discovery Sciences at AstraZeneca R&D, Sweden. He has the responsibility of
biochemical assay development for drug discovery projects at various phases. Dr. Liu obtained his Ph.D. in 2000 from Umeå University, Sweden. He
received his postdoctoral training in The Scripps Research Institute in
California with Dr. Paul Schimmel, with his research focus on the canonical and
non-canonical functions of tRNA synthetase enzymes in protein translation and
signal transduction. In 2004, Dr. Liu joined AstraZeneca R&D, Sweden. Since
then he has worked with various early drug discovery projects in the
Cardiovascular and Metabolic Disease area.
Robin Butler, Senior
R&D Manager, Protein Sciences, Antibody Discovery and Protein Engineering,
Before joining Cambridge
Antibody Technology (CAT) as a Research Scientist in 2001, I worked in research
groups in Oxford investigating a broad range of diseases, including ovarian
cancer, autosomal dominant polycystic kidney disease (ADPKD) and the genetics
of schizophrenia. I then joined Bayer Pharmaceuticals working in a team
developing small molecule therapeutics for the treatment of COPD and asthma. As
a Senior Scientist at CAT, I have been involved in supporting key therapeutic
programs during their Lead Generation phase, in the Respiratory Inflammation and
Autoimmunity (RIA) therapy area. Initially, this was through the generation of
recombinant proteins and stably transfected cell lines for use as “antigens”
and tools to develop high-throughput screens. From 2007 to date and as part of
MedImmune within the Antibody Discovery and Protein Engineering department, I
have managed two teams. The Protein Sciences RIA-aligned team supporting all
projects at the Cambridge site generating recombinant proteins, transfected
cell lines and performing affinity determination, protein biophysical analysis
and chemical modification. Also the Biologics Expression Team delivering
antibodies, antibody fragments, bispecifics and other drug modalities including
Tn3 and peptides-fusions.
Katharine Cain, Ph.D., Principal Scientist, Protein Expression and Purification Group, UCB
Cain currently works within the Protein Expression and Purification (PEP)
group at UCB in the area of mammalian cell technology and bioprocessing. Within
this group she focuses on the identification and implementation of
enhancements to both the transient mammalian expression system and early
stage cell line manufacturing. Katharine also supervises and coordinates a
number of collaborations within this area of research between UCB and academia.
Prior to working in PEP she was a member of UCB’s proprietary antibody
identification team. Katharine joined UCB nine years ago after completing a
Ph.D.at the University of Leeds, U.K. on epigenetic gene regulation.
Peter Gray, Ph.D.,
Director, Australian Institute for Bioengineering and Nanotechnology,
University of Queensland
Professor Peter Gray was appointed the
inaugural director of the Australian Institute of Bioengineering and
Nanotechnology (AIBN) at the University of Queensland in 2003. Previously he
was Professor and Head of Biotechnology at UNSW and Director of the
Bioengineering Centre, and a Senior Principal Research Fellow at the Garvan
Institute of Medical Research in Sydney. Professor Gray has had commercial
experience in the USA working for Eli Lilly and Co. and for the Cetus
Corporation and has previously held academic positions at University College
London and at the University of California, Berkeley. His research interests
are focused on engineering mammalian cells to produce the complex proteins
called biologics which are gaining rapid acceptance as human therapeutics, and
on developing human stem cells bioprocesses suitable for clinical application.
Professor Gray was one of the founders and is a past President of the
Australian Biotechnology Association, AusBiotech.
He is a Fellow of the Australian Academy of Technological Sciences and
Engineering (ATSE) and of the Australian Institute of Company Directors, and
has been named one of Australia’s 100 Most Influential Engineers. Awarded the
Centenary Medal by the Australian Government in 2001, he is a Vice President of
ATSE and serves on the boards of Biopharmaceuticals Australia Pty Ltd, ACYTE
Biotechnology Pty Ltd, Stem Cells Ltd, ECI Inc., New York, and a number of
state and federal government councils and committees.